Therapeutic potential of the

Bibliography

• HOFFMAN J, KAFATOS E JANEWAY C, EZEKOWITZ R: Phylogenetic perspectives in innate immunity. Science (1999) 284:1313–1318.
   PubMed Web of Science ®Google Scholar
• ••This review summarises recentdevelopments in the field of innate immunity.
   Google Scholar
• BOMAN HG: Gene-encoded peptide antibiotics and the concept of innate immunity: an update review. Land. Immurrol (1998) 48:15–25.
   Google Scholar
• HOFFMANN JA, REICHHART JM, HETRU C: Innate immunity in higher insects. Curi:Opirr. Immurrol (1996) 8:8–13.
   PubMed Web of Science ®Google Scholar
• METCHNIKOFF E: Lectures on the comparative pathology of inflammation. Dover Publications, New York, USA (1968).
   Google Scholar
• HIRSCH J: Phagocytin: a bactericidal substance from polymorphonuclear leukocytes. j Exp. Med. (1956) 103:589–621.
   PubMed Web of Science ®Google Scholar
• ZEYA H SPITZNAGEL J: Antibacterial and enzymatic basic proteins from leukocyte lysosomes: separation and identification. Science (1963) 142:1085–1087.
   PubMed Web of Science ®Google Scholar
• WEISS J, FRANSON RC, BECKERDITE S, SCHMEIDLER K, ELSBACH P: Partial characterization and purification of a rabbit granulocyte factor that increases permeability of Escherichia coli. j OM. Invest. (1975) 55:33–42.
   PubMed Web of Science ®Google Scholar
• HARWIG S, GANZ T, LEHRER R: Neutrophil defensins: purification, characterization, and antimicrobial testing. Meth. Errzymol. (1994) 236:160–172.
   PubMed Web of Science ®Google Scholar
• LEVY 0: Antibiotic proteins and peptides of blood: templates for novel antimicrobial agents. Blood (2000) 96:2664-2672. ccA recent review of the antimicrobialproteins and peptides of leukocytes and platelets, with emphasis on efforts towards clinical application of these natural anti-infective molecules.
   Google Scholar
• ANDERSON M ZASLOFF M: Antimicrobial peptides: complementing classical inflammatory mechanisms of defense. In: Inflammation: Basic Principles, and Clinical Correlates. J. Gallin and R. Snyderman (Eds.) Lippincott Williams & Wilkins, Philadelphia, USA (1999):1279–1292.
   Google Scholar
• SCHONWETTER BS, STOLZENBERG ED, ZASLOFF MA: Epithelial antibiotics induced at sites of inflammation. Science (1995) 267:1645–1648.
   PubMed Web of Science ®Google Scholar
• OUELLETTE AJ: Paneth cells and innate immunity in the crypt microenvironment. Gastroenterology (1997) 113:1779–1784.
   PubMed Web of Science ®Google Scholar
• GANZ T WEISS J: Antimicrobial peptides of phagocytes and epithelia. Sem. Hematol (1997) 34:343–354.
   PubMed Web of Science ®Google Scholar
• CANEY G, LEVY 0, SISSON R et al: Lipid mediator-induced expression of bactericidal/ permeaibility-increasing protein (BPI) in human mucosal epithelia. Proc. Nat. Acad. Sci. USA (2002) in press. This study is the first to demonstrate functional expression of BPI in human epithelial cells. BPI was localised to the cell surface and was inducible by a lipoxin analogue that closely resembles endogenous anti-inflammatory lipids induced by aspirin in vivo.
   Google Scholar
• HANCOCK R: Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect. D AK (2001) 1:156–164.
   PubMedGoogle Scholar
• ••Very recent review of antimicrobial peptidesincluding an update on clinical applications.
   Google Scholar
• BECKERDITE S, MOONEY C, WEISS J, FRANSON R, ELSBACH P: Early and discrete changes in permeability of Escherichia coli and certain other gram-negative bacteria during killing by granulocytes. j Ever. Med. (1974) 140:396–409.
   PubMed Web of Science ®Google Scholar
• WEISS J, ELSBACH P, OLSSON I, ODEBERG H: Purification and characterization of a potent bactericidal and membrane active protein from the granules of human polymorphonuclear leukocytes. j Biol. Chem. (1978) 253:2664–2672.
   PubMed Web of Science ®Google Scholar
• GAZZANO-SANTORO H, PARENT JB, GRINNA L et al.: High-affinity binding of the bactericidal/permeability-increasing protein and a recombinant amino-terminal fragment to the lipid A region of lipopolysaccharide. Infect. Immun (1992) 60:4754–4761.
   PubMed Web of Science ®Google Scholar
• •This study demonstrates that BPI binds to the lipid A region common to the LPS of all Gram-negative bacteria.
   Google Scholar
• WEISS J OLSSON I: Cellular and subcellular localization of the bactericidal/ permeability-increasing protein of neutrophils. Blood (1987) 69:652–659.
   PubMed Web of Science ®Google Scholar
• WEERSINK AJ, VAN KESSEL KE VAN DEN TOL ME et al.: Human granulocytes express a 55-kDa lipopolysaccharide-binding protein on the cell surface that is identical to the bactericidal/permeability-increasing protein. j ImmutioL (1993) 150:253–263.
   Google Scholar
• CALAFAT J, JANSSEN H, TOOL A et aL: The bactericidal/permeability-increasing protein (BPI) is present in specific granules of human eosinophils. Blood (1998) 91:4770–4775.
   PubMed Web of Science ®Google Scholar
• DENTENER MA, FRANCOT GJ, BUURMAN WA: Bactericidal/permeability-increasing protein, a lipopolysaccharide-specific protein on the surface of human peripheral blood monocytes. I Infect. Dis. (1996) 173:252–255.
   PubMed Web of Science ®Google Scholar
• LEVY 0, MARTINS, EICHENWALD E et al.: Impaired innate immunity in the newborn: newborn neutrophils are deficient in bactericidal/permeability-increasing protein (BPI). Pediatrics (1999) 104:1327–1333.
   Google Scholar
• •This study demonstrates relatively low levels of intracellular BPI in the neutrophils of human newborns, suggesting an age-dependent maturation in the expression of this innate defense molecule.
   Google Scholar
• GRAY PW, FLAGGS G, LEONG SR et al.: Cloning of the cDNA of a human neutrophil bactericidal protein. Structural and functional correlations. J.BioL Chem. (1989) 264:9505–9509.
   Web of Science ®Google Scholar
• BEAMER LJ, CARROLL SF, EISENBERG D: Crystal structure of human BPI and two bound phospholipids at 2.4 angstrom resolution. Science (1997) 276:1861–1864.
   Google Scholar
• ••The crystal structure of human BPIdemonstrates a bi-partite 'boomerang' shape corresponding to the molecule's N- and C-terminal halves thereby providing insight into its function.
   Google Scholar
• 001 CE, WEISS J, DOERFLER ME, ELSBACH P: Endotoxin-neutralizing properties of the 25 kD N-terminal fragment and a newly isolated 30 kD C-terminal fragment of the 55–60 kD bactericidal/ permeability-increasing protein of human neutrophils. j Exp. Med. (1991) 174:649–655.
   Google Scholar
• IOVINE NM, ELSBACH E WEISS J: An opsonic function of the neutrophil bactericidal/permeability-increasing protein depends on both its N- and C-terminal domains. Proc. Nat. Acad. Sci. USA (1997) 94:10973–10978.
   PubMed Web of Science ®Google Scholar
• •Demonstration that the C-terminal half of BPI is important to its opsonic activity.
   Google Scholar
• HORWITZ AH, LEIGH SD, ABRAHAMSON S et al.: Expression and characterization of cysteine-modified variants of an amino-terminal fragment of bactericidal/permeability-increasing protein. Protein Expr. Purif (1996) 8:28–40.
   PubMed Web of Science ®Google Scholar
• WALMSLEY RS, ZHAO MH, HAMILTON MI et al.: Antineutrophil cytoplasm autoantibodies against bactericidal/permeability-increasing protein in inflammatory bowel disease. Cut (1997) 40:105–109.
   Google Scholar
• DUNN AC, WALMSLEY RS, DEDRICK RL, WAKEFIELD AJ, LOCKWOOD CM: Anti-neutrophil cytoplasmic autoantibodies (ANCA) to bactericidal/permeability-increasing (BPI) protein recognize the carboxyl terminal domain. j Infect. (1999) 39:81–87.
   PubMed Web of Science ®Google Scholar
• MANNION BA, KALATZIS ES, WEISS J, ELSBACH P: Preferential binding of the neutrophil cytoplasmic granule-derived bactericidal/permeability increasing protein to target bacteria. Implications and use as a means of purification. j ImmutioL (1989) 142:2807–2812.
   Google Scholar
• BEAMER LJ, CARROLL SF, EISENBERG D: The three-dimensional structure of human bactericidal/permeability-increasing protein: implications for understanding protein-lipopolysaccharide interactions. Biochem. Pharmacol. (1999) 57:225–229.
   PubMed Web of Science ®Google Scholar
• MANNION BA, WEISS J, ELSBACH P:Separation of sublethal and lethal effects of the bactericidal/permeability increasing protein on Escherichia coll. JCIiii. Invest. (1990) 85:853–860.
   Web of Science ®Google Scholar
• ZANETTI M, GENNARO R, ROMEO D Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett. (1995) 374:1–5.
   PubMed Web of Science ®Google Scholar
• LEHRER RI GANZT: Antimicrobial peptides in mammalian and insect host defence. Curr. Opin. ImmutioL (1999) 11:23–27.
   PubMed Web of Science ®Google Scholar
• ••A recent review of antimicrobial peptides bythe discoverers of the defensins.
   Google Scholar
• LEVY 0, 001 CE, WEISS J, LEHRER RI, ELSBACH P: Individual and synergistic effects of rabbit granulocyte proteins on Escherichia coli. JCIiii. Invest. (1994) 94:672–682.
   Web of Science ®Google Scholar
• WRIGHT GC, WEISS J, KIM KS, VERHEIJ H, ELSBACH P: Bacterial phospholipid hydrolysis enhances the destruction of Escherichia coli ingested by rabbit neutrophils. Role of cellular and extracellular phospholipases. JCIiii. Invest. (1990) 85:1925–1935.
   Google Scholar
• WEISS J, ELSBACH E SHU C et al.: Human bactericidal/permeability-increasing protein and a recombinant NH2-terminal fragment cause killing of serum-resistant gram-negative bacteria in whole blood and inhibit tumor necrosis factor release induced by the bacteria. JCIiii. Invest. (1992) 90:1122–1130.
   Google Scholar
• ••This study demonstrates the ability of arecombinant 23 kDa N-terminal BPI fragment (rBPI23) to kill serum-resistant Gram-negative bacteria and to inhibit bacteria-induced TNF release in whole human blood tested in vitro.
   Google Scholar
• LEVY 0, SISSON R, KENYON J et al.:
   Google Scholar
• Enhancement of neonatal innate defense: Effects of adding an N-terminal recombinant fragment of bactericidal/permeability-increasing protein (rBPI21) on growth and TNF-inducing activity of Gram-negative bacteria tested in neonatal cord blood ex vivo. Infect. Immun. (2000) 68:5120–5125.
   PubMed Web of Science ®Google Scholar
• HORWITZ A, WILLIAMS R, LIU P, NADELL R: Bactericidal/permeability-increasing protein inhibits growth of a strain of Acholeplasma laidlawii and L forms of the Gram-positive bacteria Staphyloccus aureus and Streptococcus pyogenes. Antimic. Agents Chemother. (1999) 43:2314–2316.
   PubMed Web of Science ®Google Scholar
• GAVIT P BETTER M: Production of antifungal recombinant peptides in Escherichia coli. j Biotechnol. (2000) 79:127–136.
   PubMed Web of Science ®Google Scholar
• NEWMAN S, GOOTEE L, GBAY J, SELSTED M: Identification of constituents of human neutrophil azurophil granules that mediate fungistasis against histoplasma capsulatum. Infect. Immun. (2000) 68:5668–5672.
   PubMed Web of Science ®Google Scholar
• KHAN A, LAMBERT LJ, REMINGTON J,ARAUJO F: Recombinant bactericidal/ permeability-increasing protein (rBPI21) in combination with sulfadiazine is active against Toxoplasma gondii. Antimicrob. Agents Chemother. (1999) 43:758–762.
   PubMed Web of Science ®Google Scholar
• MARRA MN, WILDE CG, GRIFFITH JE, SNABLE JL, SCOTT RW: Bactericidal/ permeability-increasing protein has endotoxin-neutralizing activity. j Immunol. (1990) 144:662–666.
   PubMed Web of Science ®Google Scholar
• APPELMELK BJ, AN YQ, THUS BG, MACLAREN DM, DE GRAAFF J: Recombinant human bactericidal/ permeability-increasing protein (rBPI23) is a universal lipopolysaccharide-binding ligand. Infect. Immun. (1994) 62:3564–3567.
   PubMed Web of Science ®Google Scholar
• WIESE A, BRANDENBURG K, LINDNER B etal.: Mechanisms of action of the bactericidal/permeability-increasing protein BPI on endotoxin and phospholipid monolayers and aggregates. Biochemistry (1997) 36:10301–10310.
   Google Scholar
• •This study and the one below analyze the mechanisms by which BPI inhibits the endotoxic activities of LPS.
   Google Scholar
• TOBIAS PS, SOLDAU K, IOVINE NM, ELSBACH E WEISS J: Lipopolysaccharide (LPS)-binding proteins BPI and LBP form different types of complexes with LPS. Biol. Chem. (1997) 272:18682–18685.
   Web of Science ®Google Scholar
• OPAL SM, PALARDY JE, MARRA MN et al.: Relative concentrations of endotoxin-binding proteins in body fluids during infection. Lancet (1994) 344:429–431.
   PubMed Web of Science ®Google Scholar
• GAZZANO-SANTORO H, MESZAROS K, BIRR C et al: Competition between rBPI23, a recombinant fragment of bactericidal/permeability-increasing protein, and lipopolysaccharide (LPS)-binding protein for binding to LPS and gram-negative bacteria. Infect. Immun. (1994) 62:1185–1191.
   PubMed Web of Science ®Google Scholar
• MESZAROS K, PARENT JB, GAZZANO-SANTORO H etal.: A recombinant amino terminal fragment of bactericidal/ permeability-increasing protein inhibits the induction of leukocyte responses by LPS. Leukoc. Biol. (1993) 54:558–563.
   Google Scholar
• KOHN FR, AMMONS WS, HORWITZ A et al.: Protective effect of a recombinant amino-terminal fragment of bactericidal/ permeability-increasing protein in experimental endotoxemia. j Infect. Dis. (1993) 168:1307–1310.
   PubMed Web of Science ®Google Scholar
• LIN Y, KOHN FR, KUNG AH, AMMONS WS: Protective effect of a recombinant fragment of bactericidal/permeability increasing protein against carbohydrate dyshomeostasis and tumor necrosis factor-alpha elevation in rat endotoxemia. Biochem. Pharmacol (1994) 47:1553–1559.
   PubMed Web of Science ®Google Scholar
• EVANS TJ, CARPENTER A, MOYES D, MARTIN R, COHEN J: Protective effects of a recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in an animal model of gram-negative sepsis. j Infect. Dis. (1995) 171:153–160.
   PubMed Web of Science ®Google Scholar
• LIN Y, LEACH WJ, AMMONS WS: Synergistic effect of a recombinant N-terminal fragment of bactericidal/ permeability-increasing protein and cefamandole in treatment of rabbit gram-negative sepsis. Antimicrob. Agents Chemother. (1996) 40:65–69.
   PubMed Web of Science ®Google Scholar
• VON DER MOHLEN M, VAN DEVENTER, S, LEVI, M et al: Inhibition of endotoxin-induced cytokine release and neutrophil activation in humans by use of recombinant bactericidal/permeability-increasing protein. I Infect. Dis. (1995) 172:144–151.
   PubMed Web of Science ®Google Scholar
• ••This study and the one below demonstratethe ability of rBPI23 to inhibit multiple inflammatory activities of LPS in human volunteers.
   Google Scholar
• VON DER MOHLEN M, VAN DEVENTER S, LEVI M etal.: Inhibition of endotoxin-induced activation of the coagulation and fibrinolytic pathways using a recombinant endotoxin-binding protien (rBPI23). Blood (1995) 85:3437–3443.
   Google Scholar
• ELSBACH P, WEISS J: Prospects for use ofrecombinant BPI in the treatment of gram-negative bacterial infections. Infect. Agents Dis. (1995) 4:102–109.
   PubMedGoogle Scholar
• LEVY 0, ELSBACH P: Bactericidal/ permeability-increasing protein in host defense and its efficacy in the treatment of bacterial sepsis. Curr. Infect. Dis. Rep. (2001) 3:407–412.
   Google Scholar
• WIEZER M, MEIJER C, SIETSES C etal.: Bactericidal/permeability-increasing protein preserves leukocyte functions after major liver resection. Ann. &mg. (2000) 232:208–215.
   Google Scholar
• NU VELDT R, WIEZER M, MEIJER C et al.: Major liver resection results in a changed plasma amino acid pattern as reflected by a decreased Fischer ratio which improves by bactericidal/permeability-increasing protein. Liver (2001) 21:56–63.
   PubMedGoogle Scholar
• DEMETRIADES D, SMITH J, JACOBSEN L et al: Bactericidal/ permeability-increasing protein (rBPI21) in patients with hemorrhage due to trauma: results of a multicenter Phase II clinical trial. rBPI21 Acute Hemorrhagic Trauma Study Group. I Trauma-Injury Infect. Grit. Care (1999) 46:667–676.
   Google Scholar
• GIROIR BP, QUINT PA, BARTON P et al: Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis. Lancet (1997) 350:1439–1443.
   PubMed Web of Science ®Google Scholar
• •This Phase II open-label trial of rBPI21 in children with severe meningococcal sepsis suggested a beneficial effect and prompted the Phase III trial reported in reference 65.
   Google Scholar
• BAUER RJ, WHITE ML, WEDEL N et al: A Phase I safety and pharmacokinetic study of a recombinant amino terminal fragment of bactericidal/permeability-increasing protein in healthy male volunteers. Shock (1996) 5:91–96.
   PubMed Web of Science ®Google Scholar
• WIEZER MJ, LANGENDOEN SI, MEIJER C et al.: Pharmacokinetics of a recombinant amino terminal fragment of bactericidal/permeability increasing protein (rBPI21) after liver surgery in rats and humans. Shock (1998) 10:161-166; discussion 167–168.
   Google Scholar
• LEVIN M, QUINT P, GOLDSTEIN B et al.: Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. Lancet (2000) 356:961–967.
   PubMed Web of Science ®Google Scholar
• ••This international randomised, double- blinded, placebo-controlled Phase III trial demonstrates a beneficial effect of rBPI21 as an adjunctive therapy for children with severe meningococcal sepsis.
   Google Scholar
• GIROIR BP SCANNON PJ, LEVIN M: Bactericidal/Permeability-Increasing Protein (BPI)- Lessons learned from the Phase III, randomised, clinical trial of rBPI21 for adjunctive treatment of children with severe meningococcal sepsis. Grit Care Med. (2001) 29:5130–5135.
   Web of Science ®Google Scholar
• •A review of the results of the Phase III trial of rBPI21 for meningoccal sepsis and the implications for drug trial design in rare but rapidly progressing diseases.
   Google Scholar
• GARDNER K, HALLIDAY M, BARCLAY G et al.: Significance of systemic endotoxemia in inflammatory bowel disease. Cut (1995) 36:897–901.
   Google Scholar
• CARIO E PODOLSKY D: Differential alteration in intestinal epithelial cell expression of Toll-like receptor 3 (TLR3) and TLR4 in inflamamtory bowel disease. Infect. Immun (2000) 68:7010–7017.
   PubMed Web of Science ®Google Scholar
• GLASSER A, BOUDEAU J, BARNICH N et al: Adherent invasive Escherichia coli strains from patients with Crohn's disease survive and replicate within macrophages without inducing host cell death. Infect. Immun (2001) 69:5529–5537.
   PubMed Web of Science ®Google Scholar
• OGURA Y, BONEN DK, INOHARA N etal.: A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature (2001) 411:603–606.
   Google Scholar
• LICHTMAN SN, WANG J, SARTOR RB etal.: Reactivation of arthritis induced by small bowel bacterial overgrowth in rats: role of cytokines, bacteria, and bacterial polymers. Infect. Immun (1995) 63:2295–2301.
   Google Scholar
• OPALS, SCANNON P, VINCENT J et al:Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. j Infect. Dis. (1999) 180:1584–1589.
   PubMed Web of Science ®Google Scholar
• COOKE K, HILL G, CRAWFORD J etal.: Tumor necrosis factor-a production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft- versus-host disease. I Gun. Invest. (1998) 102:1882–1891.
   Google Scholar
• COOKE KR, GERBITZ A, CRAWFORD JM et al.: LPS antagonism reduces graft-versus-host disease and preserves graft- versus-leukemia activity after experimental bone marrow transplantation. j Gun. Invest. (2001) 107:1581–1589.
   PubMed Web of Science ®Google Scholar
• •This study demonstrates that administration of an LPS antagonist on BMT days 0 6 reduces acute GVHD and mortality in a murine model.
   Google Scholar
• WOO P, WONG S, LUMP, HUI W, YUEN K: Cell-wall-deficient bacteria and culture-negative febrile episodes in bone-marrow- transplant recipients. Lancet (2001) 357:675–679.
   PubMed Web of Science ®Google Scholar
• NELL MJ, KOERTEN HK, GROTE JJ: Bactericidal/permeability-increasing protein prevents mucosal damage in an experimental rat model of chronic otitis media with effusion. Infect Annum (2000) 68:2992–2994.
   PubMed Web of Science ®Google Scholar
• VAN DER SCHAFT DW, TOEBES EA, HASEMAN JR, MAYO KH, GRIFFIOEN AW: Bactericidal/permeability-increasing protein (BPI) inhibits angiogenesis via induction of apoptosis in vascular endothelial cells. Blood (2000) 96:176–181.
   PubMed Web of Science ®Google Scholar
• •This study reports a novel anti-angiogenic activity for BPI.
   Google Scholar
• KAUFHOLD M, PURTIC B, FADEM M, LITTLE R: Angiogenesis inhibition by synthetic peptides derived from bactericidal/ permeability-increasing protein. Proc. Am. Assoc. Cancer Res. (1997) 38:266.
   Google Scholar